Shockwave Medical, Inc. (NASDAQ:SWAV) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich cut its stake in Shockwave Medical, Inc. (NASDAQ:SWAV) by 2.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,899 shares of the company’s stock after selling 78 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Shockwave Medical were worth $743,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in Shockwave Medical by 751.7% during the 3rd quarter. SG Americas Securities LLC now owns 9,505 shares of the company’s stock worth $1,892,000 after buying an additional 8,389 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Shockwave Medical by 11.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 483 shares of the company’s stock worth $96,000 after buying an additional 50 shares during the last quarter. Linden Thomas Advisory Services LLC purchased a new position in Shockwave Medical during the 3rd quarter worth approximately $366,000. Ascent Wealth Partners LLC raised its position in Shockwave Medical by 79.3% during the 3rd quarter. Ascent Wealth Partners LLC now owns 9,961 shares of the company’s stock worth $1,983,000 after buying an additional 4,406 shares during the last quarter. Finally, Robbins Farley raised its position in Shockwave Medical by 7.3% during the 3rd quarter. Robbins Farley now owns 4,497 shares of the company’s stock worth $895,000 after buying an additional 306 shares during the last quarter. 95.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on SWAV. TheStreet raised shares of Shockwave Medical from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shockwave Medical in a report on Friday, April 5th. CL King reaffirmed a “neutral” rating on shares of Shockwave Medical in a report on Monday, April 8th. Wells Fargo & Company lifted their target price on shares of Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $335.00 target price (up from $270.00) on shares of Shockwave Medical in a report on Monday, April 8th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $309.11.

Insiders Place Their Bets

In other Shockwave Medical news, CFO Dan Puckett sold 3,406 shares of Shockwave Medical stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the sale, the chief financial officer now owns 27,732 shares of the company’s stock, valued at approximately $6,371,704.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Dan Puckett sold 3,406 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the transaction, the chief financial officer now owns 27,732 shares of the company’s stock, valued at approximately $6,371,704.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Frank T. Watkins sold 2,000 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $231.76, for a total transaction of $463,520.00. Following the transaction, the director now directly owns 4,532 shares in the company, valued at approximately $1,050,336.32. The disclosure for this sale can be found here. Insiders have sold a total of 89,813 shares of company stock valued at $22,863,919 in the last 90 days. 3.40% of the stock is owned by insiders.

Shockwave Medical Price Performance

Shares of NASDAQ SWAV opened at $330.00 on Friday. The firm has a market cap of $12.34 billion, a PE ratio of 85.27, a PEG ratio of 2.45 and a beta of 0.92. The firm has a fifty day moving average of $294.88 and a 200 day moving average of $233.41. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings results on Thursday, February 15th. The company reported $1.16 EPS for the quarter, topping the consensus estimate of $0.92 by $0.24. The company had revenue of $202.98 million during the quarter, compared to analyst estimates of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm’s revenue was up 41.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.71 EPS. As a group, research analysts predict that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.